Mihir Atreya
Has grant
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Translational approaches to unravel organ-specific microvascular endothelial responses in sepsis.
Open Date: 2024-07-01
Close Date: 2029-04-30
Grant: Close
Leveraging multi-omics to maximize the scientific value of pediatric sepsis biorepository and advance patient endotyping
Open Date: 2023-08-05
Close Date: 2025-06-30
Grant: Close
Moving Sepsis Endotyping to the Bedside
Open Date: 2023-07-01
Close Date: 2024-06-01
Grant: Close
Establishment of a multi-center biobank of patient-specific induced pluripotent stem cells for pediatric sepsis research
Open Date: 2023-05-04
Close Date: 2025-04-30
Grant: Close
The role of PCSK9-endothelial LDLR axis in the developing host with sepsis.
Open Date: 2022-07-01
Close Date: 2024-06-01
Articles (21)
Objectives: Septic shock accounts for approximately 8% of PICU admissions worldwide, carries significant morbidity, and has a reported mortality rate between 5% and 50% depending upon the geographic region in which it occurs. The high morbidity and mortality of this condition have led clinicians to consider corticosteroids when usual management does not achieve hemodynamic stability. However, the evidence for or against the use of corticosteroids in pediatric septic shock is currently unclear. Design: Pragmatic, multicenter, international, randomized, double-blinded, placebo-controlled interventional trial (ClinicalTrials.gov, NCT03401398). Setting: Approximately 50 PICUs from 11 countries in North America, South America and Asia. Patients: Up to 500 eligible pediatric patients aged one month to 17 years and 8 months with septic shock. Interventions: Patients randomized to the hydrocortisone arm receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg every six hours until all vasoactive-inotropic infusions have been discontinued for at least 12 h or for a maximum of 7 days. Patients randomized to the placebo arm receive an equivalent volume of normal saline with the identical dosing schedule. Measurements and Main Results: The primary outcome is the frequency of new or progressive multiple-organ dysfunction syndrome up to 28 days following enrollment, death or discharge, whichever comes first. The secondary outcome is a composite of the frequency of death or greater than or equal to 25% decrease in health-related quality of life from baseline, assessed at 28 days. Conclusions: The current Pediatric Surviving Sepsis Guidelines do not provide definitive recommendations regarding the use of corticosteroids in pediatric septic shock. Our study will be the first pediatric trial that is adequately powered to assess both potential benefits and adverse effects of corticosteroids in patients with septic shock. The results of this study will provide definitive data upon which to base future recommendations for corticosteroid administration in pediatric septic shock.
Year:
2026
Year:
2025
Year:
2025
Objectives: To perform: 1) external validation of the Phoenix Sepsis Score and Phoenix sepsis criteria in a multicenter cohort of critically ill children with infection and a comparison with the 2005 International Pediatric Sepsis Consensus Conference (IPSCC) criteria; 2) a study of Phoenix sepsis criteria performance in patient subgroups based on age and comorbidities; 3) an assessment of microbiological profile of children with Phoenix sepsis; and 4) a study of the performance of the Phoenix-8 score. Design: Secondary, retrospective analysis of a multicenter cohort study from 2012 to 2018. Setting: Nine PICUs in the United States. Patients: PICU admissions with suspected infection. Interventions: None. Measurements and Main Results: Among 25,680 encounters of children with suspected or confirmed infection on PICU admission (4.6% in-hospital mortality), 11,168 (43%) met Phoenix criteria for sepsis or septic shock (9% in-hospital mortality). The Phoenix criteria generally outperformed the IPSCC criteria at discriminating mortality in all critically ill children with infections and across all subgroup analyses, including age group, malignancy, or technology dependence. Of 11,168 patients who met Phoenix criteria, 28% were negative for IPSCC criteria for sepsis and these had higher in-hospital mortality than those who met IPSCC sepsis criteria but not Phoenix criteria (4.7% vs.1.7%; p < 0.001), which was similar to the mortality of patients without sepsis (1.3%). Sepsis was associated with respiratory or bloodstream infection, most commonly Pseudomonas aeruginosa or Staphylococcus aureus . The Phoenix-8 score had good discrimination of mortality in children with infections, comparable to or better than validated and widely used severity of illness and organ dysfunction scores. Conclusions: In 2012–2018, among U.S. patients with suspected or confirmed infection admitted to nine PICUs, those with the highest risk of mortality can be identified using the Phoenix sepsis criteria, including in children of different age groups and those with major comorbidities.
Year:
2025
Background Pediatric sepsis is a leading cause of global mortality, particularly among children, with limited therapeutic options beyond antibiotics and organ support. The Pediatric Sepsis Biomarker Risk Model (PERSEVERE-II) stratifies mortality risk in pediatric septic shock, yet the molecular mechanisms underlying high mortality risk remain incompletely understood. Methods We analyzed whole blood transcriptomes collected from 81 children with septic shock on day 1 of meeting study criteria. Patients were stratified into high- and low-mortality risk groups according to the PERSEVERE-II biomarker risk model. Using weighted gene co-expression network analysis (WGCNA) and differential gene expression analyses, we identified molecular pathways and transcription factors (TFs) associated with mortality risk. Cell type differences were inferred using CIBERSORTx and using a reference single-cell dataset inclusive of neutrophils and their subsets. Findings We identified distinct molecular profiles with high-risk patients displaying significant overexpression of genes related to neutrophil degranulation and innate immunity, alongside suppressed adaptive immune responses. The predominance of developing neutrophils underscored a major role of emergency granulopoiesis. Key TFs identified, including LTF , FOXM1 , KLF1 , and CEBPB , were linked to high-risk gene expression signatures. Our findings indicate a pathological shift toward a dysregulated neutrophil-driven hyperinflammation and adaptive immune suppressive state, which together are associated with adverse outcomes. Interpretation Our results suggest that neutrophil dysregulation underpins the high mortality risk conferred by the PERSEVERE-II model. The identified transcriptional regulators may provide potential targets to mitigate neutrophil dysregulation and improve outcomes among high-risk patients.
Year:
2025
Year:
2025
Year:
2025
Introduction: Several transcriptomic signatures for sepsis have been proposed but none have translated into clinical practice. How these signatures relate to each other is unclear and this lack of consensus remains a barrier to implementation. We investigated whether these signatures could be leveraged to develop a consensus immune dysregulation framework with prognostic and therapeutic relevance. Methods: The SUBSPACE consortium is an international group of sepsis investigators who have shared whole blood bulk RNA sequencing data. We co-normalized 3,013 samples across 10 SUBSPACE sepsis cohorts and applied seven transcriptomic signatures.We performed network analysis on scaled scores using Spearman correlation to identify edges. We integrated 254 samples (602,338 cells) from 4 publicly available sepsis peripheral blood single cell RNA-seq (scRNA-seq) datasets inclusive of the neutrophil compartment to identify the cellular origin of these consensus clusters. We applied these biologic insights to develop a framework for quantifying myeloid and lymphoid dysregulation in sepsis. The association of dysregulation with 30-day mortality was evaluated using Fisher's exact test. The association of dysregulation with treatment response was evaluated in two randomized controlled trials: (1) the SAVE-MORE trial (anakinra in COVID-19); and (2) the VICTAS trial (hydrocortisone, thiamine, and vitamin C in sepsis). Patients in VICTAS who received open-label steroids were excluded. Outcomes were assessed using Fisher's exact test and interaction terms were generated using logistic regression. Results: Network analysis identified four clusters of scores: two clusters associated with high-risk and two with low risk. Using scRNA-seq data, we found that these score clusters separate along myeloid and lymphoid lineages. We derived myeloid and lymphoid dysregulation scores by combining applied signatures and defined dysregulation as a z-score >1.65 relative to healthy controls. Dysregulation was associated with an odds ratio of 1.9 for 30-day mortality (95% CI 1.4-2.7, p = 4.7e-5, Figure 1A,B). In SAVE-MORE (n = 391), anakinra therapy in COVID-19 patients with lymphoid dysregulation was associated with reduced mortality (OR = 0.02, Fisher p=0.02, p(interaction) = 0.05, Figure 1C). In VICTAS (n = 89), hydrocortisone, vitamin C, and thiamine therapy in sepsis patients with lymphoid dysregulation was associated with reduced 30-day mortality (OR = 0.19, Fisher p = 0.05, p(interaction) = 0.05, Figure 1D). Neither treatment improved mortality in patients without lymphoid dysregulation in either trial. Conclusion: The consensus immune dysregulation framework quantifies myeloid and lymphoid dysregulation in sepsis. Dysregulation is associated with increased mortality and differential response to treatment with anakinra and hydrocortisone.
Year:
2025
Year:
2025
Introduction Neonatal sepsis remains a leading cause of global childhood mortality, yet treatment options are limited. Clinical and biological heterogeneity hinders the development of targeted therapies. Gene-expression profiling offers a potential strategy to identify neonatal sepsis subtypes and guide targeted intervention. Methods We performed secondary analyses of publicly available gene-expression datasets. Differential gene expression analysis and T-distributed Stochastic Neighbor Embedding (t-SNE) identified biologically relevant patient clusters. Mortality and organ dysfunction were compared across clusters to determine clinical relevance. Results We identified three endotypes of neonatal sepsis based on the 100 gene expression mortality signature, distinguishing five non-survivors from 72 survivors across datasets. Compared with other endotypes, Endotype A was associated with high mortality (22% vs. 0%, p=0.003) and cardiac dysfunction (61% vs. 31%, p=0.025). Pathobiology among endotype A patients was primarily driven by neutrophil progenitors. Conclusions Gene-expression profiling can be used to disentangle neonatal sepsis heterogeneity. Dysregulated hyperinflammatory response with emergency granulopoiesis was pathognomonic of high-risk endotype A. Pending further validation, gene-expression-based subclassification may be used to identify at-risk neonates and inform the selection of targeted sepsis therapies.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (17)
Jennifer Kaplan
Cincinnati Children's Hospital Medical Center
Brian Varisco
Professor, Vice Chair for Research
University of Arkansas for Medical Sciences
Hjalmar R. Bouma
Internist-Acute Medicine/Pharmacologist
University Medical Center Groningen
Ananthakrishnan Ganesan
Senior Data Scientist
Stanford University
Jonathan Byrnes
The University of Alabama
Basilia Zingarelli
Professor/Director of Basic Science Research
Cincinnati Children's Hospital Medical Center
Joseph Levitt
Associate Professor
Stanford University
Robinder G. Khemani
University of Southern California
Stephen Standage
Clinical Associate Professor
University of Cincinnati
Lieuwe D. J. Bos
University of Amsterdam
Brendon Scicluna
Senior Lecturer
University of Malta
Charles Langelier
Associate Professor
UCSF Medical Center
Karen Choong
Professor
McMaster University
Angela Rogers
Professor
University of Texas Southwestern Medical Center
James Williams
Assistant Professor
University of Arkansas for Medical Sciences
Purvesh Khatri
Professor
Stanford University School of Medicine
Andrew Lautz
Research Associate Professor
Cincinnati Children's Hospital Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.